Cytomed enters research collaboration agreement with Sengkang General Hospital

CytoMed Therapeutics announced that it has entered into a research collaboration agreement, or RCA, with Sengkang General Hospital, a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, umbilical cord-derived mesenchymal stem cells, or UC-MSCs, to treat cartilage injury. This injectable therapy will be implemented in vivo to support the application and commencement of a proposed Phase 1 clinical trial in Singapore, and is anticipated to complete within two years. The use of MSC as a potential treatment for tissue regeneration, inflammatory and regenerative diseases has been the subject of increasing interest in the global scientific community. Osteoarthritis of the knee is a debilitating disease affecting Singapore’s aging population and the clinical trial will pioneer stem cell use for regenerative medicine in Singapore. Under the RCA, CytoMed will provide the allogeneic UC-MSC, processed and expanded in its own state-of-the-art GMP laboratory while SKH will provide the infrastructure, manpower and scientific data analysis.